Results 261 to 270 of about 461,819 (327)
Interleukin‐1 receptor type II and inflammatory bowel disease: A Mendelian randomization study
This Mendelian Randomization study investigated the association between interleukin‐1 receptor type II (IL‐1RII) and inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC) by utilizing the genome‐wide association studies summary statistics.
Qifan Feng+7 more
wiley +1 more source
Biotin/sulfasalazine combination therapy alleviates acetic acid-induced ulcerative colitis in rats via modulation of S1PR1/NF-κB/IL-23/STAT3/COX-2 axis. [PDF]
Helmy SA+3 more
europepmc +1 more source
A systematic review and meta‐analysis were conducted to review all clinical trial results of anifrolumab for treating systemic lupus erythematosus. Fourteen studies were included comprising 1322 patients and five studies were meta‐analyzed. It was found that anifrolumab 300 mg IV led to clinical improvement across composite lupus scores, cutaneous ...
Yomna W. Mahmoud+11 more
wiley +1 more source
Increased Colonic Levels of CD8+ Cytotoxic T lymphocyte-Associated Mediators in Patients With Microscopic Colitis. [PDF]
Lushnikova A+5 more
europepmc +1 more source
There was a positive correlation between apnea/hypopnea index (AHI) index and platelet aggregation and a negative correlation between CD42b and multidrug resistance protein 1 (MRP1). Platelet activation was high while MRP1 expression was low in severe obstructive sleep apnea syndrome (OSAS) independent of smoking, age, and gender.
Cigdem Bayram Gurel+8 more
wiley +1 more source
Disease Burden and Unmet Medical Needs in Patients with Ulcerative Colitis in Greece: A Cross-Sectional Patient Survey. [PDF]
Gourzoulidis G+4 more
europepmc +1 more source
Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing
The review highlights nature‐inspired nanocarriers for CRISPR delivery, emphasizing viral vectors, extracellular vesicles, liposomes, and lipid nanoparticles. It discusses their roles in improving specificity, minimizing immunogenicity, and overcoming barriers in genome editing. Recent advancements, challenges, and therapeutic applications are explored,
Elizabeth Maria Clarissa+4 more
wiley +1 more source